“Balance” seems to be the keyword for the next drug pricing reform in FY2024. Japan now appears ready to seek a better balance between evaluating innovative medicines and taking tough measures against companies dependent on long-listed products (LLPs) and generic…
HOME > ORGANIZATION
ORGANIZATION
- Rapid Removal of NHI-Market Price Gap Will Cause Chaos: Pharmacy Industry Chief
September 9, 2022
- JMA President Confirms Need for Profits from NHI-Market Price Gap
September 8, 2022
- Ex-MHLW Official Isobe, Now at Self-Medication Group, Touts OTC Use to Soften Impact of Off-Year Re-Pricing
September 7, 2022
- Chuikyo Payer Rep Eyes 5%-Plus Discrepancy Threshold or Broader Coverage: 2023 Off-Year Re-Pricing
September 5, 2022
- FPMAJ Chief Advocates Drug Price Revision Rule Based on Appropriate Margins for Each Player
September 2, 2022
- JPMA Proposes New Value-Based Pricing System for Innovative Meds, No Price Cut in Patent Period
August 31, 2022
- JPMA Urges Govt to Expand Support to Boost Competitiveness of Japan Pharma Industry
August 31, 2022
- Allocate All Savings from Off-Year Drug Re-Pricing to Medical Fees: Hodanren
August 31, 2022
- JaDHA Hopes to Issue First Policy Proposal to Solve Digital Health Challenges by Year-End: Chairman
August 17, 2022
- Single-Wholesaler Distribution Should Be Redressed from Stable Supply Standpoint: JMA Official
August 4, 2022
- JPWA Chief Questions Patient Benefits of Single-Wholesaler Distribution
August 1, 2022
- Veterans’ Group Proposes Timely Drug Re-Pricing with Online Data, Reimbursement at Actual Purchase Prices
July 27, 2022
- JPMA Delays Announcement of Drug Pricing Proposal
July 27, 2022
- JPMA Hails New Expert Panel, Plans to Raise “Drug Loss” Issue: Director General
July 25, 2022
- Savings from Off-Year Drug Re-Pricing Should Go Towards Medical Fees: JMA Chief
July 15, 2022
- FPMAJ Lauds Ruling Bloc Election Win, Urges Drastic Social Security Debate
July 12, 2022
- FPMAJ Chief Thanks Abe for AMED Launch, Vows to Carry On Innovative Drug Discovery
July 12, 2022
- Regenerative Medicine Makers Have “Good Reasons” to Opt for Single-Wholesaler Route: FIRM Chair
July 12, 2022
- JPMA Think Tank Finds Surge in Japan-Unapproved Drugs in Areas with High Unmet Needs
July 12, 2022
- JPMA Committed to Building Drug Discovery Ecosystem: President
July 5, 2022
ページ
Companies don’t plan to fail when it comes to recruitment, but many fail to plan. What happens if your marketing director resigns? A recruiting plan gives your organization the confidence in knowing that whatever happens, there is a process in…
Is policy intervention necessary for Japanese drug makers reliant on off-patent brand-name medicines? Many members of the health ministry’s key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…